Levonorgestrel/Ethinyl Estradiol

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Premenstrual Syndrome

Conditions

Premenstrual Syndrome

Trial Timeline

Jul 1, 2005 → Aug 1, 2006

NCT ID

NCT00161681

About Levonorgestrel/Ethinyl Estradiol

Levonorgestrel/Ethinyl Estradiol is a phase 3 stage product being developed by Pfizer for Premenstrual Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT00161681. Target conditions include Premenstrual Syndrome.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00447863	Phase 1	Withdrawn	Aug 1, 2007	Aug 1, 2007	Contraception
NCT00319163	Phase 1	Completed	May 1, 2006	Nov 1, 2006	Healthy
NCT00195559	Phase 3	Completed	Sep 1, 2005	Dec 1, 2007	Premenstrual Syndrome
NCT00128934	Phase 3	Completed	Aug 1, 2005	Dec 1, 2007	Menstruation Disturbances
NCT00161681	Phase 3	Completed	Jul 1, 2005	Aug 1, 2006	Premenstrual Syndrome

Competing Products

5 competing products in Premenstrual Syndrome

See all competitors

Product	Company	Stage	Hype Score
paroxetine	Novo Nordisk	Approved	84
Levonorgestrel/Ethinyl Estradiol	Pfizer	Phase 3	76
Levetiracetam	UCB	Pre-clinical	20
Drospirenone and ethinyl estradiol + Placebo	Bayer	Pre-clinical	20
EE20/DRSP(YAZ, BAY86-5300) + Placebo	Bayer	Phase 3	74

Other Products from Pfizer